A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.

The genito-urinary syndrome of menopause severely affects patients with a history of gynecological cancer, especially those diagnosed with breast cancer. At the present time, we do not have solid scientific evidence on treatments that can be effective and safe to address this pathology. Based on the above, we have developed our working hypothesis where it is postulated that the microfractionated laser treatment of C02, in conjunction with topical regenerative treatment, constitute an effective alternative in the management of vulvo-vaginal atrophy in oncological patients who have contraindicat

Trial Details

NCT ID
NCT05585476
Phase
NA
Sponsor
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • C02 microablative laser
  • Regenerative topical treatment
Locations (sample)
  • Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Patients must meet ALL of the following criteria to be included in the study:
  • Patients over 18 years of age
  • Who have a history of breast malignancy, and are on adjuvant or neoadjuvant treatment with hormone therapy.
  • That they suffer symptoms related to vulvo-vaginal atrophy and thus become evident to the gynecological examination (Vaginal Health Index\<ó=15).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →